ReviewThe Journal of allergy and clinical immunology2023
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.
Review in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Causal relationships of metabolites with allergic diseases: a trans-ethnic Mendelian randomization study.Respiratory research · 2024Pooled it
- Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases.Frontiers in immunology · 2024Pooled it
- Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.The Journal of infectious diseases · 2024Trial
- Best evidence for managing cutaneous immune-related adverse events in cancer: A summary from Chinese and English literature.Asia-Pacific journal of oncology nursing · 2026Review
- Beyond the drug: autoimmune predisposition to DRESS syndrome.Proceedings (Baylor University. Medical Center) · 2026Article
- HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms.JAMA network open · 2026Article
- Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine-Current Status and Future Prospects.International journal of immunogenetics · 2026Review
- HIV as a Host Susceptibility State for Severe Drug Hypersensitivity: Disentangling Biological Susceptibility from Drug Exposure in the FAERS Database.medRxiv : the preprint server for health sciences · 2026Article
- Toxic Epidermal Necrolysis Mimicking Severe Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Diagnostic Challenge.Journal of clinical medicine · 2026Article
- Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER.CNS neuroscience & therapeutics · 2026Article
- Immunological Interplay at the Ocular Surface of Stevens-Johnson Syndrome, Ocular Cicatricial Pemphigoid, and Ocular Graft Versus Host Disease.Investigative ophthalmology & visual science · 2026Review
- Association between HLA alleles and adverse drug reactions. Mechanisms involved.Advances in laboratory medicine · 2026Review
- Genetic Variants Associated with Non-Steroidal Anti-Inflammatory Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Medical sciences (Basel, Switzerland) · 2026Article
- In vitro diagnostics of drug hypersensitivity reactions.Allergologie select · 2026Review
- Risk factors for cutaneous immune-related adverse events: a systematic scoping review.Frontiers in immunology · 2026Article
- Evaluating Baricitinib for Severe Paediatric Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) with Single-Cell Sequencing.Journal of inflammation research · 2026Article
- Carbamazepine activates private self and viral reactive TCRs through a drug-permissive HLA-B cleft.Frontiers in immunology · 2026Article
- Case Report: Toxic epidermal necrolysis induced by sintilimab in a patient with advanced lung squamous cell carcinoma.Frontiers in pharmacology · 2026Article
- Risk factors and predictive score for phenytoin-induced cutaneous reactions.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Stevens-Johnson syndrome as the presenting manifestation of human immunodeficiency virus and syphilis coinfection.Dermatology online journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, toxic epidermal necrolysis (SJS/TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS) cause significant morbidity and mortality and impede new drug development. HLA class I associations with SJS/TEN and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome have aided preventive efforts and provided insights into immunopathogenesis. In SJS/TEN, HLA class I-restricted oligoclonal CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.